Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
27/06/2024 14:00
June 27 (Reuters) - Verona Pharma's VRNA.O therapy for
treating a chronic lung disease will be sold in the U.S. at a
wholesale price of $2,950 per month, the U.K.-based company said
on a conference call on Thursday.
The U.S. health regulator's assent on Wednesday for the
therapy, branded as Ohtuvayre, provides a new inhaled
non-steroidal treatment for chronic obstructive pulmonary
disease.
(Reporting by Pratik Jain in Bengaluru; Editing by Shounak
Dasgupta)
((Pratik.Jain@thomsonreuters.com))
Recent news on Verona Pharma
See all newsBrief: Acquisition Of Verona By Msd Approved By The High Court Of Justice Of England And Wales
Brief: Shareholders Of Verona Pharma Approve Proposed Acquisition By Merck
US corporate debt market returns in force after market holiday
Merck to cut jobs and costs as demand for Gardasil in China remains weak (updated)
Merck to cut jobs and costs as demand for Gardasil in China remains weak